Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 138

1.

Pancreatic cancer cell lines deficient in argininosuccinate synthetase are sensitive to arginine deprivation by arginine deiminase.

Bowles TL, Kim R, Galante J, Parsons CM, Virudachalam S, Kung HJ, Bold RJ.

Int J Cancer. 2008 Oct 15;123(8):1950-5. doi: 10.1002/ijc.23723.

2.

Arginine deiminase as a novel therapy for prostate cancer induces autophagy and caspase-independent apoptosis.

Kim RH, Coates JM, Bowles TL, McNerney GP, Sutcliffe J, Jung JU, Gandour-Edwards R, Chuang FY, Bold RJ, Kung HJ.

Cancer Res. 2009 Jan 15;69(2):700-8. doi: 10.1158/0008-5472.CAN-08-3157.

3.
4.

Arginine deiminase augments the chemosensitivity of argininosuccinate synthetase-deficient pancreatic cancer cells to gemcitabine via inhibition of NF-κB signaling.

Liu J, Ma J, Wu Z, Li W, Zhang D, Han L, Wang F, Reindl KM, Wu E, Ma Q.

BMC Cancer. 2014 Sep 20;14:686. doi: 10.1186/1471-2407-14-686.

5.

Arginine deprivation as a targeted therapy for cancer.

Feun L, You M, Wu CJ, Kuo MT, Wangpaichitr M, Spector S, Savaraj N.

Curr Pharm Des. 2008;14(11):1049-57. Review.

6.

Renal cell carcinoma does not express argininosuccinate synthetase and is highly sensitive to arginine deprivation via arginine deiminase.

Yoon CY, Shim YJ, Kim EH, Lee JH, Won NH, Kim JH, Park IS, Yoon DK, Min BH.

Int J Cancer. 2007 Feb 15;120(4):897-905.

7.
8.

Induction of arginosuccinate synthetase (ASS) expression affects the antiproliferative activity of arginine deiminase (ADI) in melanoma cells.

Manca A, Sini MC, Izzo F, Ascierto PA, Tatangelo F, Botti G, Gentilcore G, Capone M, Mozzillo N, Rozzo C, Cossu A, Tanda F, Palmieri G.

Oncol Rep. 2011 Jun;25(6):1495-502. doi: 10.3892/or.2011.1220. Epub 2011 Mar 18.

PMID:
21424129
9.

Arginine deiminase PEG20 inhibits growth of small cell lung cancers lacking expression of argininosuccinate synthetase.

Kelly MP, Jungbluth AA, Wu BW, Bomalaski J, Old LJ, Ritter G.

Br J Cancer. 2012 Jan 17;106(2):324-32. doi: 10.1038/bjc.2011.524. Epub 2011 Dec 1.

10.
11.

Targeting argininosuccinate synthetase negative melanomas using combination of arginine degrading enzyme and cisplatin.

Savaraj N, Wu C, Li YY, Wangpaichitr M, You M, Bomalaski J, He W, Kuo MT, Feun LG.

Oncotarget. 2015 Mar 20;6(8):6295-309.

12.

Arginine deprivation using pegylated arginine deiminase has activity against primary acute myeloid leukemia cells in vivo.

Miraki-Moud F, Ghazaly E, Ariza-McNaughton L, Hodby KA, Clear A, Anjos-Afonso F, Liapis K, Grantham M, Sohrabi F, Cavenagh J, Bomalaski JS, Gribben JG, Szlosarek PW, Bonnet D, Taussig DC.

Blood. 2015 Jun 25;125(26):4060-8. doi: 10.1182/blood-2014-10-608133. Epub 2015 Apr 20.

13.

Arginine deprivation by arginine deiminase of Streptococcus pyogenes controls primary glioblastoma growth in vitro and in vivo.

Fiedler T, Strauss M, Hering S, Redanz U, William D, Rosche Y, Classen CF, Kreikemeyer B, Linnebacher M, Maletzki C.

Cancer Biol Ther. 2015;16(7):1047-55. doi: 10.1080/15384047.2015.1026478. Epub 2015 Mar 16.

14.
15.

Hypoxia-induced nitric oxide production and tumour perfusion is inhibited by pegylated arginine deiminase (ADI-PEG20).

Burrows N, Cane G, Robson M, Gaude E, Howat WJ, Szlosarek PW, Pedley RB, Frezza C, Ashcroft M, Maxwell PH.

Sci Rep. 2016 Mar 14;6:22950. doi: 10.1038/srep22950.

16.

Arginine deiminase resistance in melanoma cells is associated with metabolic reprogramming, glucose dependence, and glutamine addiction.

Long Y, Tsai WB, Wangpaichitr M, Tsukamoto T, Savaraj N, Feun LG, Kuo MT.

Mol Cancer Ther. 2013 Nov;12(11):2581-90. doi: 10.1158/1535-7163.MCT-13-0302. Epub 2013 Aug 26.

17.

Argininosuccinate synthetase (ASS) deficiency in high-grade pulmonary neuroendocrine carcinoma: an opportunity for personalized targeted therapy.

Walts AE, Bomalaski JS, Ines D, Orsulic S.

J Cancer Res Clin Oncol. 2015 Aug;141(8):1363-9. doi: 10.1007/s00432-014-1904-z. Epub 2014 Dec 30.

PMID:
25548129
18.

Activation of Ras/PI3K/ERK pathway induces c-Myc stabilization to upregulate argininosuccinate synthetase, leading to arginine deiminase resistance in melanoma cells.

Tsai WB, Aiba I, Long Y, Lin HK, Feun L, Savaraj N, Kuo MT.

Cancer Res. 2012 May 15;72(10):2622-33. doi: 10.1158/0008-5472.CAN-11-3605. Epub 2012 Mar 29.

19.

Selective Intracellular Delivery of Recombinant Arginine Deiminase (ADI) Using pH-Sensitive Cell Penetrating Peptides To Overcome ADI Resistance in Hypoxic Breast Cancer Cells.

Yeh TH, Chen YR, Chen SY, Shen WC, Ann DK, Zaro JL, Shen LJ.

Mol Pharm. 2016 Jan 4;13(1):262-71. doi: 10.1021/acs.molpharmaceut.5b00706. Epub 2015 Dec 17.

20.

Negative argininosuccinate synthetase expression in melanoma tumours may predict clinical benefit from arginine-depleting therapy with pegylated arginine deiminase.

Feun LG, Marini A, Walker G, Elgart G, Moffat F, Rodgers SE, Wu CJ, You M, Wangpaichitr M, Kuo MT, Sisson W, Jungbluth AA, Bomalaski J, Savaraj N.

Br J Cancer. 2012 Apr 24;106(9):1481-5. doi: 10.1038/bjc.2012.106.

Supplemental Content

Support Center